The New Zealand Government is advancing legislation to permit the commercial sale of oral nicotine pouches, prompting public health researchers to question the evidentiary basis of a policy that disregards documented health risks and youth dependency.
Declassified Cabinet documents reveal plans to introduce oral nicotine products (ONPs) to the market under the rationale of supporting national smokefree goals. However, the proposal excludes previous Ministry of Health guidance that advised against commercialisation due to potential harms and adolescent appeal.
In a briefing published by the Public Health Communication Centre (PHCC), researchers noted that proven nicotine replacement therapies and vaping products are already widely accessible to adult smokers seeking to quit.
“There needs to be a robust assessment of the potential harms and benefits of ONPs before proceeding with any legislation,” said PHCC Science Lead Calvin Cochran.
Nicotine pouches – small sachets placed between the lip and gum – are manufactured primarily by multinational tobacco firms, including Philip Morris International and British American Tobacco. While industry representatives frame ONPs as reduced-risk alternatives, manufacturers market them primarily as lifestyle products rather than regulated cessation aids.
International Pushback and Youth Marketing Concerns
The domestic push comes amid rising international caution. The World Health Organization issued a warning regarding predatory youth marketing of ONPs, urging governments to enforce sales bans and tight marketing controls.
Several countries have introduced strict market barriers:
- Australia: Prohibited the personal importation of ONPs without a prescription.
- Canada, France, and the UK: Enacted specialized distribution limits and youth access safeguards.
Health specialists caution that introducing another recreational nicotine category could duplicate the regulatory challenges seen with youth vaping.
“New Zealand risks repeating the experience of youth vaping if these products are allowed to be widely marketed,” Cochran warned.
